The TPM3‐NTRK1 fusion gene has been increasingly recognized as a driver alteration in diverse soft tissue and mesenchymal tumors, with significant implications for diagnosis and targeted therapy. This evidence concerns the gene NTRK1 and mesenchymal cell neoplasm.